ライフサイエンスコーパス: efficacy and safety

1 markers and clinical outcomes, providing reassuring data on efficacy and safety.

2 We present an integrated efficacy and safety analysis of patients with metastatic or l

3 ofile in phase 1 clinical trials and is being evaluated for efficacy and safety as monotherapy in patients with mild to m

4 DMET) properties of drug candidates are important for their efficacy and safety as therapeutics.

5 wnstream versus the upstream strategy on the combination of efficacy and safety events (net clinical benefit).

6 The efficacy and safety of a combination of the two compounds in

7 The efficacy and safety of a reduced dose of prasugrel versus a s

8 This study aimed to determine whether the efficacy and safety of a therapeutic strategy involving low-d

9 We aimed to assess the efficacy and safety of atezolizumab (anti-PD-L1) alone and co

10 IMpassion031 compared efficacy and safety of atezolizumab versus placebo combined w

11 ut prior exposure to TNF-alpha antagonists, (2) comparative efficacy and safety of biologic monotherapy vs combination th

12 Evidence supports the efficacy and safety of both in-office and facility-based surg

13 Treatment of Moderate to Severe Plaque Psoriasis], and -3 [Efficacy and Safety of Brodalumab Compared With Placebo and U

14 The objective of this review was to compare the efficacy and safety of conservative surgery with or without a

15 In the United States, the efficacy and safety of convalescent plasma for treating coron

16 The efficacy and safety of dapagliflozin were consistent across t

17 severe UC are complex, with limited guidance on comparative efficacy and safety of different treatments, leading to consi

18 This systematic review and meta-analysis compared the efficacy and safety of DOACs and low-molecular-weight heparin

19 -analysis of ten randomized clinical trials to evaluate the efficacy and safety of DOACs in patients with CAT.

20 The efficacy and safety of dolutegravir (DTG) were assessed in ad

21 Long-term efficacy and safety of Fluticasone propionate/formoterol fuma

22 We aimed to measure the efficacy and safety of gabapentin in women with chronic pelvi

23 The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhi

24 We performed a trial to evaluate the efficacy and safety of IW-3718, a bile acid sequestrant, as a

25 We aimed to evaluate the efficacy and safety of ixekizumab, an IL-17 inhibitor, in non

26 e aimed to confirm results on long-term outcome focusing on efficacy and safety of long-term use of rituximab maintenance

27 We aimed to assess the efficacy and safety of mavacamten, a first-in-class cardiac m

28 In this retrospective study, we compared the efficacy and safety of mechanical adjuvants in mucosal-sparin

29 The objective of this study was to assess the efficacy and safety of nabilone, a synthetic tetrahydrocannab

30 Herein, the 12-month efficacy and safety of netarsudil/latanoprost FDC are reporte

31 ouble-blind, double-dummy, phase 2 trial to investigate the efficacy and safety of once-weekly insulin icodec as compared

32 A randomised phase 3 clinical trial assessing the efficacy and safety of pembrolizumab versus placebo in combin

33 Longer and larger trials are necessary to evaluate the efficacy and safety of sodium phenylbutyrate-taurursodiol in

34 As metabolism impacts the efficacy and safety of therapeutic peptides and proteins (TPP

35 We assessed the efficacy and safety of ticagrelor versus prasugrel in a head-

36 ADVANCE compared the efficacy and safety of two antiretroviral first-line combinat

37 with advanced medullary thyroid cancer (MTC) to assess the efficacy and safety of vandetanib in patients with progressiv

38 Hence, we sought to evaluate the efficacy and safety of VIT in HVA patients with cMCD.

39 This Phase 2 clinical study evaluated the efficacy and safety of VT-1161 versus fluconazole in subjects

40 The aim of this retrospective study was to compare the efficacy and safety profile of a single XEN-microstent in dif

41 However, its efficacy and safety remain unclear.

42 ation and after 2 weeks, as primary surrogate end points of efficacy and safety, respectively.

43 Here we report updated efficacy and safety results from a prespecified, interim, ove

44 These results through 96 weeks support the efficacy and safety results reported previously for doravirin

45 arative clinical study differs from a traditional phase III efficacy and safety study in the development of a novel biolo

46 Findings on secondary efficacy and safety/tolerability outcome measures in Asian pa

47 The Randomized Efficacy and Safety Trial of Oral GABA(A) alpha5 antagonist S

48 release was sustained for almost 2 months and the material efficacy and safety was proven both in vitro and in vivo.

49 monstrated that the brolucizumab q12-week regimen maintains efficacy and safety while reducing treatment burden associate

50 This study demonstrates high efficacy and safety with contemporary S-ICD devices and progr